

## **DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF \$750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZER**

BREAKTHROUGH PATENT-PENDING TRACER DEVELOPED FOR BROAD USE

NEW YORK, MARCH 15, 2021-- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a phase-two contract from the United States Air Force (USAF) to implement a novel fluorescent tracer and optical sensing technology into a next-generation point-of-care blood volume analyzer. This is the fourth contract award Daxor has received from the Department of Defense (DoD) in the past two years, totaling more than \$2 million dollars for the manufacture of advanced blood volume analyzers for military and civilian applications.

“We are pleased to share with the public our innovative fluorescing tracer and optical blood volume diagnostic program which has been awarded a \$750,000 contract from the USAF. This contract will further enhance the capabilities for our state-of-the-art technology making precise blood volume measurement both easier and quicker in both combat casualty care and civilian settings,” said Michael Feldschuh, President and CEO of Daxor. “Daxor’s BVA-100 Blood Volume Analysis (BVA) technology transforms the existing standard of care by ensuring resuscitation and transfusion treatment decisions are based on precise measurement of blood volume for better patient survival and outcomes. Our next-generation system promises to be even faster, easier, and usable in a broader range of care settings from the battlefield to the outpatient clinic to bedside in the ICU.”

“This represents a significant milestone for our technology. The invention of a novel fluorescent tracer optimized for blood volume measurement, for which we have several patents pending, will expand use of our test into more clinical settings for more indications,” said Jonathan Feldschuh, Chief Scientific Officer of Daxor. “This tracer will support our next generation optical analyzer allowing for point-of-care measurement expanding our product offerings to include both nuclear and fluorescing-based testing options. We are excited to accelerate our development under this contract with the DoD.”

The phase-two funding was made possible through the highly competitive SBIR program of AFWERX, the USAF team of innovators who encourage and facilitate connections across industry, academia, and the military to create transformative opportunities for the development of rapid and affordable commercial and military technologies and solutions that meet critical healthcare needs.

## About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at [Daxor.com](http://Daxor.com).

## Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### **Investor Relations Contact:**

Bret Shapiro

Sr. Managing Partner, CORE IR

516-222-2560

[brets@coreir.com](mailto:brets@coreir.com)

## **DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES**

NEW YORK, August 4, 2020 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into a Cooperative Research and Development Agreement (“CRADA”) with The Uniformed Services University of the Health Sciences (“USU”), an institution of higher learning within the United States Department of Defense (DoD), and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on behalf of USU’s Battlefield Shock and Organ Support Research Program (BSOS). The partnership includes researching the effectiveness of Daxor’s BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury.

“Diagnostics currently used to guide battlefield resuscitation and transfusions, such as heart rate, cardiac output, stroke volume, and blood pressure, often misdiagnose the severity of volume derangement,” said Michael Feldschuh, CEO and President of Daxor. “Daxor’s BVA-100 Blood Volume Analysis (BVA) technology can greatly improve the existing standard of care by ensuring treatment decisions based on precise measurement of blood volume for better trauma survival outcomes.”

Extensive peer-reviewed medical literature has validated Daxor’s BVA's enhancement of interventions through reliable and accurate blood volume measurement. Most relevant to military medicine is a prospective randomized controlled trial which demonstrated that, compared to standard care, actionable BVA-100 information changed surgical intensive care unit (SICU) fluid and red blood cell interventions by 44% of cases while reducing patient mortality by 66%. Additionally, it cut patients’ length of stay and days on a ventilator.

The collaboration will encompass multiple projects with the ultimate objective of saving the lives of American soldiers and translating the results to civilian care. Target indications include hemorrhage, burn, trauma, sepsis and acute respiratory distress syndrome.

“Collaborating with USU and HJF is an important milestone as we have been working on new technology and filed patent applications to extend the capabilities of our current FDA-cleared diagnostic system, the BVA-100, for both civilian and military use,” said Jonathan Feldschuh, Chief Scientific Officer at Daxor. “The results of this work will also support work on the next generation BVA device currently in development under a separate contract with the Department of Defense.”

### About Daxor Corporation

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at [Daxor.com](http://Daxor.com).

### About HJF

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a global nonprofit organization with the mission to advance military medicine. HJF's scientific, administrative and program operations services empower investigators, clinicians, and medical researchers around the world to make discoveries in all areas of medicine. With more than 35 years of experience, HJF serves as a trusted and responsive link between the military medical community, federal and private partners, and the millions of warfighters, veterans, and civilians who benefit from military medicine. For more information, visit [hjf.org](http://hjf.org).

### Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



## **Daxor Awarded \$1.1 Million Contract from United States Department of Defense (DOD) for Rapid Portable Blood Volume Analyzer**

**New York, NY, April 23, 2020 - Daxor Corporation** (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the United States Department of Defense (DOD) has awarded the Company a \$1.1 million contract for the development and deployment of a small, portable, highly accurate, battery-powered Blood Volume Analyzer.

"The value of Blood Volume Measurement for improving outcomes is further validated by this important contract from the U.S. Military for our technology," commented Daxor Corporation's Chief Executive Officer Michael Feldschuh. "Whether helping to treat COVID-19 patients in the hospital setting as we are doing now, or helping with trauma and burn patients in the military or civilian setting, Daxor's current and future systems are a leap forward from the current standard of care for volume assessment and provide better patient results in numerous settings."

In order to improve combat casualties, Daxor, alongside the DOD, developed a small, portable, highly accurate, battery-powered prototype of its flagship product, the BVA-100. To ensure optimal delivery, Daxor has ramped up its research and production capabilities to prioritize this contract and plans to generate significant production capabilities in the next 18 months. The Company believes this contract further validates the value of its blood volume technology, as this prototype, which has been under development for the past two years, promises to improve casualty care in saving many more lives within the armed forces.

"We are developing innovative instrumentation that is faster and simpler to use, capable of giving complete volume status in as little as 12 minutes," commented Jonathan Feldschuh, Chief Science Officer of Daxor. "Building on Daxor's core technology, the new device will enable caretakers and clinicians to make precise and timely decisions for medication administration and determining patient-specific treatment."

Once the Company moves into mass-manufacturing the advanced device, both parties agree that this new technology is also suitable for civilian use in hospitals and outpatient settings. Moreover, with its framework tied to hospitals and ICUs, Daxor will have the ability to bring this new technology to the broader health care market.

"This is an important step forward for Daxor as the DOD has indicated that Daxor's next generation blood volume technology may provide an important addition to military medicine, recognizing its essential need

within civilian medical applications,” added Soren Thompson, the Company’s Vice President of Development.

Daxor was first selected by the Government’s Small Business Innovative Research (SBIR) department in 2018. Following close collaboration and continued development between Daxor and the Department of Defense, Daxor will begin execution of the contract as specified in the agreement beginning May 1, 2020. Daxor has filed multiple new patents with the United States Patent and Trademark Office related to the development of the technology and support of its features.

Daxor's BVA-100 has been used in over 45,000 patient clinical assessments as well as featured in over 100 published research studies, trials, poster presentations, and case studies from leading institutions such as the Mayo Clinic, Cleveland Clinic, the VA, Yale University School of Medicine, Christiana Care Health System of Newark, Vanderbilt University Medical Center, Virginia Commonwealth University, and Queen's Medical Center among others.

### **About Daxor Corporation**

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information please visit our website at [Daxor.com](http://Daxor.com).

### **Forward-Looking Statements**

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### **Investor Relations Contact:**

Bret Shapiro Sr. Managing  
Partner, CORE IR  
516-222-2560  
[brets@coreir.com](mailto:brets@coreir.com)



## **Daxor Corporation Contracted to Adapt Its Blood Volume Analyzer Technology for U.S. Air Force Needs**

**NEW YORK – March 9, 2020 - Daxor Corporation (NYSE MKT: DXR)**, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Air Force (USAF) has awarded Daxor a contract to define specifications to adapt blood volume analysis technology to meet the needs of USAF.

The selection was made under the USAF's Small Business Innovative Research (SBIR) program. The contract award will be to validate the product-market fit between Daxor's blood volume analyzer and USAF stakeholders and define technological enhancements desirable to facilitate adoption of the device by USAF and other defense stakeholders.

"Daxor looks forward to adapting its technology to provide time sensitive, mission critical care information and decision support to the specially trained personnel within the Air Force," said Michael Feldschuh, CEO of Daxor Corporation.

"This opportunity enables us to continue to push our research and development program forward, opening new applications for our technology" says Jonathan Feldschuh, Chief Scientific Officer. "We are focused on making blood volume measurement simpler and quicker to perform, whether in an aircraft, a field hospital, or at the patient bedside."

This is the second award for Daxor with the Department of Defense (DoD). SBIR contracts are designed to stimulate innovation by companies to develop technologies and solutions that meet critical Army needs. SBIR programs benefit the DoD and the private sector and support the nation's economic growth.

### **About Daxor Corporation**

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information please visit our website at <https://www.daxor.com>

### **Forward-Looking Statements**

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without

limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### **Investor Relations Contact**

Bret Shapiro  
Sr. Managing Partner, CORE IR  
516-222 -2560  
[brets@coreir.com](mailto:brets@coreir.com)

**Investor Relations Contact:**

Bret Shapiro

Sr. Managing Partner, CORE IR

516-222-2560

[brets@coreir.com](mailto:brets@coreir.com)



## **Daxor Corporation Selected for U.S. Army Contract to Develop a Blood Volume Analyzer for Improvement of Combat Casualty Care**

**NEW YORK – November 7, 2018 - Daxor Corporation (NYSE MKT: DXR)**, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Army has selected it for a contract award to develop a blood volume analyzer for improving combat casualty care.

The selection was made under the Defense Department's Small Business Innovative Research (SBIR) program. The contract award will be to develop and demonstrate a prototype blood volume analyzer suitable for military use leveraging Daxor's technology and experience with blood volume measurement devices. "Hemorrhage is the primary cause of death in about 30% of injured soldiers," said Michael Feldschuh, CEO of Daxor Corporation. "Direct blood volume measurement has been shown to improve outcomes in a broad range of acute and chronic medical conditions. Our existing technology platform and patent portfolio is an ideal foundation for developing a rapid, rugged, portable blood volume analyzer that can improve prehospital resuscitation on the battlefield, potentially saving many lives."

"This is an exciting additional opportunity to push our research and development program forward," says Jonathan Feldschuh, Chief Scientific Officer. "We are focused on making volume measurement easier and quicker to perform, whether in a hospital lab, on the battlefield, or at the patient bedside."

This is a first-time award for Daxor. SBIR contracts are designed to stimulate innovation by companies to develop technologies and solutions that meet critical Army needs. SBIR programs benefit the Department of Defense (DoD) and the private sector and support the nation's economic growth.

### **About Daxor Corporation**

Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient's blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately the company's mission is to help hospitals and physicians incorporate Daxor's BVA-100 diagnostic to significantly improve the quality of patient care. For more information please visit our website at <http://www.daxor.com>.

### **Forward-Looking Statements**

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Investor Relations Contact:

Bret Shapiro  
Sr. Managing Partner  
CORE IR  
561-479-8566  
[brets@coreir.com](mailto:brets@coreir.com)